- Resource
- BR1DGE
- Disease Burden
- Management
- Video
Technology Advances and the Persistent Burden of T1D – ATTD 2026
The video discusses how advances in insulin delivery have yet to translate into improved population-level glycemic outcomes
Learning Objectives
- Understand the impact of health inequities on DKA presentation at T1D diagnosis
- Recognize that advances in insulin delivery technology have not fully translated into improved population-level glycemic outcomes for people with T1D
- Identify the daily demands of T1D management beyond device use, including the continuous decision-making required around diet, activity and daily life
Summary
At ATTD 2026, Dr Renuka Dias examines the ongoing burden of T1D despite significant advances in insulin delivery technology. In the UK, improvements in hybrid closed-loop uptake did not increase the proportion of patients achieving glycemic targets, highlighting the gap between technological progress and real-world outcomes. The video also notes that diagnosis often occurs at DKA presentation, especially in underserved populations. Beyond glycemic control, the daily demands of living with T1D underscore the burden that persists for individuals and families.
MAT-GLB-2601655 - 1.0 - 04/2026
The Importance of Preserving Residual Beta-Cell Function in T1D
Maintaining residual beta-cell function in T1D improves glycemic control, reduces complications, and impacts care and outcomes in people with T1D.
Supporting islet-autoantibody-positive individuals and their families
Appropriate strategies can help support people with early-stage T1D and their families and address anxiety during early T1D monitoring, ensuring optimal engagement and care.
Early T1D Screening Recommendations
Expert insights on recommendations for T1D screening, including proposed age ranges and opportunities for integration into existing public health touchpoints.